Amikacin News and Research

RSS

USPTO issues composition of matter patent for Transave's ARIKACE

Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026.

25 May 2010

WHO estimates 440 000 MDR-TB cases in 2008

In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says.

19 Mar 2010

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.

14 Sep 2009

Clinical data on CXA-101 to be presented at ICAAC

Calixa Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, will present pre-clinical and clinical data in 20 posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in San Francisco on September 12 to 15, 2009.

14 Sep 2009

Lancet Infectious Diseases examines spread of XDR-TB

The journal Lancet Infectious Diseases examines the worldwide spread of extensively drug-resistant tuberculosis (XDR-TB). Currently, about 500,000 of the 9 million new cases of TB that are identified each year are strains of XDR-TB. "Drug resistance is largely man-made - it is vitally important to review antibiotic treatment strategies and to ensure the Stop TB Strategy is fully applied to prevent further selection of drug-resistant mutants," Leonard Amaral of Universidade Nova de Lisboa said.

24 Jun 2009

XDR-TB declining in the U.S.

A new report suggests that the number of cases of extensively drug-resistant tuberculosis (XDR-TB) in the U.S. has declined in the past fifteen years, but new cases continue to be reported, according to the study published in the November 12 issue of JAMA.

11 Nov 2008

Increasing transmission of drug resistant tuberculosis in the UK

A changing population structure and ongoing migration have increased cases of drug resistant tuberculosis, according to a study published on bmj.com today.

1 May 2008

WHO ready to tackle drug resistant TB

According to the World Health Organization (WHO) some forms of tuberculosis (TB) are a threat to the security and stability of global health.

25 Jun 2007

New plan to contain extensively drug-resistant TB (XDR-TB)

Hundreds of thousands of cases of drug-resistant tuberculosis (TB) can be prevented and as many as 134 000 lives saved through the implementation of a two-year response plan, published/launched today by the World Health Organization (WHO) and the Stop TB Partnership.

22 Jun 2007